Contergan Victim Wins Against Former Board Member of the Contergan Foundation

Food and Healthcare Press Releases Thursday June 8, 2017 09:32
COLOGNE, Germany--8 Jun--PRNewswire/InfoQuest

In the lawsuit between the plaintiff, Contergan (thalidomide) victim Andreas Meyer, and the defendant and former Board member of the Contergan Foundation, Attorney Karl Schucht, the Bonn Regional Court came to a judgement on 10.5.2017. The judgement is not yet final. The case concerns the question of possible collaboration between Gruenenthal and the Federal German Contergan Foundation.

Meyer was and will be represented by Prof. Dr. Jan Hegemann from the law firm Raue Rechtsanwalte LLP in Berlin.
Please refer the full press release dated 08.06.2017 at: http://www.gruenenthal-opfer.de/press_ContVict_wins_agains_memb_ContFound_8_6_2017
You can read the judgement and further information at the following link:
http://www.gruenenthal-opfer.de/Materials_Judgement_Meyer_vs_Schucht_10_05_2017
Contact:
Federation of Thalidomide Sufferers and Gruenenthal Victims
c/o Mr Andreas Meyer (Chairman)
Dohmengasse 7
50829 Koln
Email: bcg-brd-dachverband@gmx.de
Website: www.gruenenthal-opfer.de
Mobile: +49 (0)172 / 2905974
Source: Federation of Thalidomide Sufferers and Gruenenthal Victims

Latest Press Release

Swift Announces the Highest Throughput Single-Cell Methyl-Seq Library Preparation Method

Study published in Science magazine demonstrates how epigenetic markers can identify cell subtypes and regulatory elements that drive cellular diversity Swift Biosciences, a leading provider of innovative library prep solutions for next-generation...

Making it Easier to Understand Nutrition Labels

The Nutrition Facts label can provide you with lots of useful information—as long as you know how to read it correctly. Reading nutrition labels can be a challenge, because it always seems confusing and complicated. Oftentimes, you are discouraged...

Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

- Collaboration furthers both parties' commitment to advance research and development for neglected diseases - Agreement focuses on optimizing vaccine process development and formulation and exchanging know-how Merck , a leading science and technology...

NICE Recommends Erbitux(R) in Combination with Platinum-Based Chemotherapy for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer in the Oral Cavity

- Decision secures access to Erbitux(R) for new patients in England with oral cavity tumors - All patients currently receiving Erbitux(R) will have continued access Merck, a leading science and technology company, announced today that the National...

European Patent Office to Grant Merck#s Patent Application for CRISPR Technology

- Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - Related patent application recently awarded in Australia; similar patents pending in other countries, favourable outcomes...

Related Topics